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Background: Development of anticancer drugs is challenging. Indeed, much research effort 
has been spent in the development of new drugs to improve clinical outcomes with minimal 
toxicity. We have previously reported that a formulation of lipid gold porphyrin nanoparticles 
reduced systemic drug toxicity when compared with free gold porphyrin. In this study, we 
investigated the delivery and treatment efficiency of PEG surface-modified lipid nanoparticles 
as a carrier platform.
Methods: We encapsulated antitumor drugs into PEG-modified lipid nanoparticles and these 
were characterized by size, zeta potential, and encapsulation efficiency. The delivery efficiency 
into tumor tissue was evaluated using a biodistribution study. To evaluate antitumor efficacy, 
gold porphyrin or camptothecin (a DNA topoisomerase I inhibitor) were encapsulated and 
compared using an in vivo neuroblastoma (N2A) model.
Results: We showed that drug encapsulation into PEG-modified lipid nanoparticles enhanced 
the preferential uptake in tumor tissue. Furthermore, higher tumor killing efficiency was observed 
in response to treatment with PEG-modified lipid nanoparticles encapsulating gold porphyrin 
or camptothecin when compared with free gold porphyrin or free camptothecin. The in vivo 
antitumor effect was further confirmed by study of tumor inhibition and positive apoptosis 
activity. Surface modification of lipophilic nanoparticles with PEG increased the efficiency of 
drug delivery into tumor tissue and subsequently more effective antitumor activity.
Conclusion: This specific design of a chemotherapeutic agent using nanotechnology is impor-
tant in the development of a safe and effective drug in cancer therapy.
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Introduction
Chemotherapy is essential for the treatment of a variety of cancers. Although the use 
of modern anticancer drugs has improved the clinical outcome for patients with a wide 
range of cancers, the same could not be said for neuroblastoma, which is the most 
common solid tumor in childhood.1 This is because this tumor often presents with 
only few symptoms in the early clinical stages. Furthermore, patients often become 
refractory to available drugs very quickly. Thus, there is an urgent need for newer 
agents if we are to improve the overall survival of these patients.
It has been estimated that approximately one third of potent anticancer drugs are 
hydrophobic. A recently developed chemotherapeutic agent, gold (III) porphyrin 
(GP), is a water-insoluble inorganic metal complex and has been demonstrated to have 
 efficacy against a wide range of cancers.2–4 Indeed, its antitumor activity is 100-fold 
more potent than cisplatin, an agent commonly used for treating neuroblastoma.2,3 
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Possible mechanisms of tumor killing include induction of 
apoptosis, the mitochondria-mediated apoptotic pathway, and 
 production of reactive oxygen species.5 Similarly, another 
potent anticancer drug, camptothecin, features a closed hydro-
phobic lactone ring.6 Although the  hydrophobicity of camp-
tothecin results in more favorable antitumor activity, such as 
against hepatocellular, ovarian, breast, and renal tumors,7–10 
its clinical application is limited because of severe systemic 
organ damage associated with significant side effects.6 Its 
in vivo toxicity has been reported to be correlated with low 
solubility and instability in the aqueous environment.11
Drug encapsulation via an optimal delivery system is an 
integral part of drug design to overcome the issues of  systemic 
toxicity as well as to improve the efficiency of drug delivery. 
A number of studies have focused on the design of carriers for 
delivery to provide optimal incorporation of drugs.12–14 To the 
best of our knowledge, effective  encapsulation of hydrophobic 
drugs into a carrier for the treatment of neuroblastoma has 
not yet been reported. With evolution in nanotechnology, 
the design of a drug delivery system with more controllable 
physical properties has shown promising results in enhanc-
ing antitumor activity in target tumor tissue.15 Tumor vas-
culature is characterized uniquely with leaky blood vessels, 
which allow nanoparticles greater than 100 nm in diameter 
to pass through.16 Thus, larger  nanoparticles of 100–200 nm 
in diameter are ideal for delivery into tumor tissue and 
consequently can reduce renal clearance and uptake by the 
reticuloendothelial system.17 This phenomenon is called the 
“enhanced permeability retention” effect.15
For our delivery system, we used lipid nanoparticles 
consisting of cetyl alcohol and Brij 78 to incorporate 
GP, because they have been shown to have excellent 
 biocompatibility in blood.18 The formulation strategy was 
to incorporate a  microemulsion into a lipid nanoparticle 
carrier in distilled water as opposed to the organic solvents 
used in the synthesis of most other formulations. The sol-
vent was carefully chosen in order to address the common 
problem of additional toxicity associated with use of an 
organic solvent. In our previous study, surface modification 
of lipid nanoparticles was shown to reduce the toxicity of 
GP, both in vitro and in vivo.19 In this work, we investigated 
the treatment efficiency of a lipophilic carrier by physical 
characterization, tumor accumulation, systemic distribution, 
and antitumor activity. To examine further the efficiency of 
a lipophilic carrier platform for delivery, we encapsulated 
camptothecin into the lipophilic carrier and investigated the 
activity and therapeutic effect of lipophilic-encapsulated 
camptothecin.
Materials and methods
Synthesis of PEgylated nanoparticles
Gold (III) porphyrin 1a was manufactured and kindly  provided 
by the Department of Chemistry at Hong Kong  University.20 
Camptothecin was purchased from Sigma- Aldrich (St Louis, 
MO). The GP and camptothecin  nanoparticles were prepared as 
previously described using an oil/water (o/w)  microemulsion.19 
Briefly, the drug was melted into the oil phase of cetyl alcohol 
at 60°C. Brij 78, a surfactant, was added to the oil phase and 
stirred for 5  minutes. Methoxypoly(ethylene glycol) (mPEG 
750–2000 Da, 5 mol%) was added to the nanoparticle tem-
plate and mixed well by stirring. The particle size and surface 
charge of the nanoparticles was measured using a Zetasizer 
 Nanoseries (Malvern, Westborough, MA). Then, 10 µL of 
each sample was added to 1 mL of 1:100 (v/v) phosphate-
buffered saline (pH 7.4) in distilled water for the zeta potential 
study, as previously described.21
Encapsulation efficiency
Drug entrapment efficiencies were determined by separat-
ing free GP from the GP nanoparticles (GPNP) using a 
Centrisart I centrifugal ultrafiltration unit (Supleco, Belle-
fonte, PA) with a filter membrane (molecular weight cutoff 
10 kDa) as described elsewhere,22 and then measuring the 
GP in nanoparticle-containing supernatants using induc-
tively coupled plasma-mass spectroscopy. About 1 mL of 
the formulation solution was put in the outside chamber 
and in the recovery chamber at the top. After separation by 
centrifugation at 4000 rpm for 30 minutes, GPNP remained 
in the outer chamber while free GP was in the recovery 
chamber. To ensure mass balance, the filtrates were also 
assayed for GP. GP loading and entrapment efficiency were 
calculated as follows:
Percent drug entrapment efficiency = (GP entrapped in NP) 
  /(Total GP added into NP preparation) × 100%
Tumor cell lines and in vitro  
cytotoxicity test
A murine glioblastoma (D54) or neuroblastoma (N2A) 
cell line was seeded in a 96-well plate at a density of 
8 × 103 cells/well and cultured in Dulbecco’s Modified 
Eagle Medium supplemented with 10% fetal bovine serum 
and 1% penicillin/streptomycin at 37°C. An MTT assay was 
performed after incubation of the lipophilic nanoparticle-
encapsulated drugs for 24 and 72 hours. Normal fibroblasts 
was seeded at a density of 8000 cells/well in a 96-well 
plate. The MTT assay was performed according to the 
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manufacturer’s protocol after  incubation of the lipophilic 
nanoparticle-encapsulated drugs for 4 hours. Briefly, 10 µL 
of MTT substrate was added into each well and incubated 
for 4 hours at 37°C, after which 100 µL of solubilization 
buffer was added to each well and incubated overnight. The 
absorbance measurement was  performed at 540 nm with the 
reference filter at 650 nm using an absorbance microplate 
reader (BioRad, Hercules, CA).
In vivo neuroblastoma model
Six- to eight-week-old male A/J mice weighing 20 ± 2 g 
were obtained and housed in the Laboratory Animal 
Unit, University of Hong Kong. The experimental proto-
col was approved by the Committee on the Use of Live 
Animals for Teaching and Research, University of Hong 
Kong (CULATR 1901-09). The animals were cared for 
humanely. N2A tumor-bearing mice were created by sub-
cutaneous injection of 200 µL of a mouse neuroblastoma 
cell line (N2A) at a density of 1.5 × 106/mL suspended in 
phosphate-buffered saline into the right flank of the mouse. 
At 8–11 days after inoculation, tumor mass became vis-
ible and measurable at the injection site. Tumor growth 
was evaluated by measuring the tumor volume using 
morphometric analysis with calipers every other day 
until 21 days.
Chemotherapy using 3–5 mg/kg of free GP, GPNP, 
or GPNP surface-coated with PEG (GPNP-PEG) was 
 administered intraperitoneally after the tumor became 
 visible and the dose was chosen according to our previous 
report.19 Intraperitoneal administration was selected because 
this route has been demonstrated to be an effective and 
well tolerated systemic route as compared with intravenous 
administration to treat neuroblastoma.23–26 Tumor volume 
was calculated as height × weight × length. Body weight 
was measured every other day until 21 days. Percentage 
survival was determined by the number of mice surviving 
at the designated time points.
Biodistribution study of gold porphyrin
The liver, kidneys, and tumor tissue were harvested from 
each mouse, which was either untreated or had received 
3 mg/kg (0.06 mg/20 g) of free GP or GPNP conjugated 
with or  without PEG at 6 and 24 hours. The harvested tissues 
were acid-digested as previously described.27  Biodistribution 
analysis was conducted by measuring the gold isotope 
 concentration (ppb) with inductively coupled plasma-mass 
spectroscopy in the Bioengineering  Department at the 
 University of Science and Technology, Hong Kong.
TUNEL assay
A TUNEL assay was performed on 5 mm tumor  paraffin 
sections using a commercially available kit (Roche 
Applied Science, Gilroy, CA) according to the manufac-
turer’s  instructions. Briefly, the tissue was fixed in 4% 
 paraformaldehyde, dehydrated, paraffin-embedded, and 
sectioned. The section was then deparaffinized,  rehydrated, 
and pretreated with 0.02 mg/mL of proteinase K in 0.1 mM 
Tris-HCl pH8 buffer for 10 minutes. The TUNEL assay was 
performed by incubating fluorescein-conjugated  terminal 
deoxynucleotidyl transferase in enzyme solution for 2 hours. 
The stained section was viewed using a  fluorescent 
 microscope under a blue filter.
Statistical analysis
The statistical analyses were performed using Student’s paired 
t-test; a P value , 0.05 was considered to be  statistically 
significant. The α value adjustment was made by Bonferroni 
correction for multiple comparisons. The data are presented 
as the mean ± standard deviation.
Results and discussion
We synthesized lipophilic nanoparticles using cetyl alcohol 
and Brij 78 surfactant. This lipophilic formulation had been 
developed earlier in our laboratory to incorporate lipophilic 
GP, and we showed that GPNP had a significant reduction in 
side effects when compared with free GP in a  neuroblastoma 
model.19 Nonetheless, prolonged administration of this 
early formulation still resulted in systemic toxicity due to 
 accumulation in the liver.
In this study, we surface-coated GPNP with PEG 
to  investigate if this modification could enhance drug 
 delivery into tumor tissue and also reduce systemic 
uptake. The lipophilic nanoparticles with or without 
surface  modification were first characterized (Table 1). 
More than 90% of  hydrophobic GP was encapsulated into 
PEG-coated  lipophilic nanoparticles. The zeta potential 
of GP, GPNP, and GPNP-PEG ranged from −4.13 mV 
Table 1 Biophysical characterization of lipophilic carrier for-
mulations and free gP. The results are presented as the mean ± 
standard deviation
Formulations Particle size 
(nm)
Zeta potential 
(mV)
Encapsulation 
efficiency
gP  10.91 ± 6.02 −12.49 ± 6.03
gPNP  104.4 ± 18.5  −4.13 ± 8.19
gPNP-PEg 164.47 ± 6.9   −8.5 ± 2.72 98% of gP
Abbreviations: gP, gold porphyrin; gPNP, gold porphyrin nanoparticles; 
gPNP-PEg, gold porphyrin nanoparticles surface-coated with PEg.
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Another requirement of a carrier system in cancer 
therapy is the ability to facilitate the antitumor  activity 
of the active drug. Our in vitro study investigated the 
 activity of the  encapsulated drug against tumor cells. Here, 
MTT assay showed that greater cell death was seen in the 
N2A  neuroblastoma cell line using encapsulated GP in a 
 dose-dependent manner (Figure 2A).
This would suggest that the lipophilic carrier facilitated 
antitumor activity against N2A. In order to confirm if our car-
rier template could enhance antitumor activity of other drugs, 
we tested camptothecin, another potent hydrophobic drug, 
using the same carrier system, whereby the PEG-coated lipo-
philic carrier also enhanced antitumor activity. The IC
50
 of 
N2A for GPNP was 0.002 mM as compared with 0.005 mM 
of GP, and was 0.0025 mM for  camptothecin-NP or camp-
tothecin-NP-PEG and 0.03 mM for free  camptothecin. This 
result indicated that lipophilic carrier enhanced drug efficacy 
by 2–10-fold.
On the other hand, because insertion of long-chained 
PEG provided steric hindrance to prevent cellular and serum 
 protein interaction, we investigated whether the  composition 
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Figure 2 (A) Dose-dependent antitumor activity against N2 A for gP and camptothecin 
with or without the lipophilic carrier formulation (n = 4, *P , 0.05 when comparing 
nanoparticle formulation with free gP or camptothecin). (B) Comparison of surface-
coated lipophilic nanoparticle carrier with different molecular weights (750 Da and 
2000 Da) of PEg.
Notes: Results are presented as the mean ± standard deviation (n = 4, *P , 0.05 for 
C-PEg 750 or C-PEg 2000 in comparison with C).
Abbreviations: C, camptothecin; gP, gold porphyrin; gPNP, gold porphyrin 
nanoparticles; gPNP-PEg, gold porphyrin nanoparticles surface-coated with PEg.
to −12.49 mV,  suggesting a slight change in value but 
within a low negative range of net surface charge after 
PEG modification, possibly due to nanoparticle encap-
sulation. The low negative value of the surface charge 
would mean that the favorable binding affinity for cells 
remained unchanged after encapsulation.28 Direct light 
scattering measurements in Table 1 showed that encap-
sulation increased the size of GPNP compared with GP. 
The addition of PEG further increased the size of the 
lipophilic nanoparticles from 101.9 nm to 164.4 nm with-
out a significant change in zeta potential or  morphology. 
This would benefit delivery into tumor tissue via the 
enhanced  permeability retention effect. Because the pore 
sizes of the liver fenestrae are around 100 nm and the gap 
sizes of the tumor vessels are  approximately 400 nm,29–31 
we  hypothesized that  GPNP-PEG could evade uptake 
by the liver, with enhanced tumor uptake. This is indeed 
shown in Figure 1. Here, accumulation of free GP in the 
liver was 336 ppb Au/g tissue at 6 hours, and decreased 
to 112 ppb Au/g tissue at 24 hours, while both the kidney 
and tumor tissue showed minimal uptake (,30 ppb Au/g 
tissue) at 6 and 24 hours, respectively. The unconjugated 
GPNP showed comparable uptake in the liver and kidney 
(18 ppb Au/g  tissue and 52 ppb Au/g tissue, respectively) 
and relatively high tumor uptake at 6 hours. At 24 hours, 
uptake of unconjugated GPNP by the liver increased but 
was not significantly  different from that in tumor tissue. 
On the other hand, GPNP-PEG showed only minimal liver 
and kidney uptake (6–44 ppb Au/g tissue), whilst uptake 
in tumor tissue was significantly higher (468 ppb Au/g 
tissue and 392 ppb Au/g tissue, respectively, P , 0.05) 
at 6 and 24 hours. This finding would explain the reduced 
systemic toxicity after encapsulation into a PEG surface-
coated lipophilic carrier.
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Figure 1 Tissue residence of free gP, gPNP, and gPNP-PEg at 6 and 24 hours. 
Notes: Data are presented as the ppb Au/g tissue ± standard deviation (*P , 0.05, n = 3). 
Abbreviations: gP, gold porphyrin; gPNP, gold porphyrin nanoparticles; gPNP-PEg, 
gold porphyrin nanoparticles surface-coated with PEg.
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Figure 4 Apoptotic activity of (A) gP formulations and (B) camptothecin formulations 
using Tunel assay in neuroblastoma tissue harvested at 21 days after treatment. 
Notes: green represents positive apoptotic cells and blue represents the DAPI nuclei 
stain. Magnification 100× (left column) or 200× (right column); n = 5, *P , 0.05 for 
4 mg/kg or 5 mg/kg of gPNP-PEg in comparison with untreated controls in Figure 4A.
Abbreviations: gP, gold porphyrin; gPNP-PEg, gold porphyrin nanoparticles 
surface-coated with PEg.
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Figure 3 Tumor volume measurements after N2A-bearing A/J mice had received 
intraperitoneal injections of gPNP-PEg 3, 4, or 5 mg/kg. 
Notes: n = 5–6, *P , 0.05.
Abbreviation: gPNP-PEg, gold porphyrin nanoparticles surface-coated with PEg.
of PEG would interfere with the antitumor activity of the 
encapsulated drug. Indeed, less antitumor activity was 
found when the nanoparticle carrier was coated with higher 
molecular weight PEG (PEG 2000), as compared with lower 
molecular weight PEG (PEG 750), as shown in Figure 2B.
We next investigated the in vivo therapeutic effect of 
GPNP-PEG using a neuroblastoma model. As shown in 
Figure 3, GPNP-PEG doses of 3, 4 and 5 mg/kg all had 
a significant antitumor effect by inhibiting the growth of 
N2A cells when compared with the control (P , 0.05). The 
antitumor effect decreased after the first 7 days but could be 
sustained by repeated doses.
Because evasion of cell death is an indicator of drug 
resistance,32 we further studied tumor cell apoptosis using the 
TUNEL assay after treatment with the lipophilic nanoparticle 
 carrier. Figure 4 demonstrates that apoptotic activity was 
significantly higher in the GPNP-PEG-treated neuroblas-
toma line than in the untreated neuroblastoma line. Similar 
 findings was also recorded when camptothecin-PEG was 
given. Taken together, positive tumor inhibition as well as 
apoptosis indicates that our nanoparticle carrier system was 
effective against neuroblastoma.
Nonetheless, a logical extension of our carrier system 
would be to show its usefulness against other aggressive 
cancers. Here we have shown that our lipophilic carrier 
enhanced the efficacy of GP and camptothecin against D54, 
an aggressive glioblastoma cell line (Figure 5). This would 
suggest that our lipophilic nanoparticle system is adaptable, 
and therefore promising as a new therapeutic approach 
against a range of cancers. Further work has indeed been 
planned in this direction.
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Figure 5 Dose-dependent antitumor activity against D54.
Notes: Results are presented as the mean ± standard deviation (n = 4, *P , 0.05 for 
C-NP or C-PEg 2000 compared with C).
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To summarize, drug encapsulation into a PEGylated 
lipid nanoparticle carrier may further improve drug accu-
mulation inside tumor tissue with low accumulation in the 
liver and provide effective antitumor activity in vitro and 
in vivo.
Conclusion
Our GPNP-PEG formulation offers a new strategy for the 
development of a safe and effective carrier for drug treatment 
of cancer. Clinical studies are eagerly awaited.
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